Results 71 to 80 of about 38,621 (286)
ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
Quantification of hCM Action Potential Waveform Following Direct hMSC-hCM Electrical Interactions.
, 2016 To further explore the effects of each family of hMSC, we quantified the relationship between (A) APD, (B) VAPD/2, (C) RMP, and the percentage of coupled (left panel) or fused (right panel) hMSCs in a homogeneously distributed hMSC-hCM population.
Eric A. Sobie (242595) +3 more
core +1 more source
Integrating HCM Tools: Best Practices and Case Studies [PDF]
, 2018 In the modern business landscape, effective Human Capital Management (HCM) is pivotal for organizational success. The integration of HCM tools into existing HR systems is a strategic endeavor that can enhance workforce management, streamline HR processes,
Reddy Kommera, Harish Kumar
core +2 more sources
Annals of Cardiac AnaesthesiaThe Doppler-derived gradient depends on the magnitude of the flow across a narrowed orifice and the alignment of the Doppler with the flow. Septal myectomy is indicated in symptomatic obstructive hypertrophic cardiomyopathy (HCM) patients with peak ...
Devika Poduval +5 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li +12 more
wiley +1 more source
Mutation screening in sarcomeric genes in Italian HCM paediatric population
, 2009 Introduction and Aim: The hypertrophic cardiomyopathy (HCM) is a primary disease of the heart muscle, transmitted by an autosomal dominant character, with a highly variable penetrance and expressivity, even within the same family cluster.
P. Calabrò +8 more
core
HCM Clinical: An Interactive Knowledge Resource for HCM Diagnosis, Monitoring, and Treatment
, 2021 Hypertrophic cardiomyopathy (HCM), which is the most common genetic cardiac disease, is diagnosed by the presence of ventricular hypertrophy in the absence of any abnormal loading conditions causing it. Clinical manifestations of HCM are highly variable—individuals with HCM can either be asymptomatic or exhibit dyspnea, fatigue, palpitations, chest ...
Mila, Glavaški, Lazar, Velicki
openaire +2 more sources
Considerations for drug trials in hypertrophic cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source
Left ventricular remodeling in hypertrophic cardiomyopathy patients with atrial fibrillation
BMC Cardiovascular Disorders, 2018 Background Atrial fibrillation (AF) is the most common complication in hypertrophic cardiomyopathy (HCM). The mechanisms of AF is associated with left atrial (LA) structural remodeling in HCM patients.
Hongwei Tian +8 more
doaj +1 more source